Abstracts tagged "signal transduction and systemic sclerosis"

Abstract Number: 1106 • 2018 ACR/ARHP Annual Meeting
Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Peripheral Blood Mononuclear Cells of Systemic Sclerosis Patients: Correlation with Disease Specific Manifestations
Fabio Cacciapaglia¹, Simone Perniola^2,3, Livio Urso¹, Emanuela Praino⁴, Rita Bizzoca², Dorotea Natuzzi², Nunzia Lacarpia² and Florenzo Iannone⁵, ¹Department of Emergency and Organs Transplantation (DETO); University of Bari (Italy), Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy, ²Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy, ³Department of Verona - University of Verona (ITALY), Verona, Italy, ⁴DIM, Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy, ⁵D.E.T.O., Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy
Background/Purpose: Signal transducer and activator of transcription 3 (STAT3) is a transcription factor regulated by phosphorylation of key tyrosine residues that regulates pivotal cell processes…
Abstract Number: 1924 • 2015 ACR/ARHP Annual Meeting
Increased Stat1 and Stat 1 Phosphorylation in Patients with Systemic Sclerosis (SSc)
Martyna Skwarek, Julia Fantana, Babett Heschel, Martin Aringer and Christoph Kittel, Medicine III, University Medical Center and Faculty of Medicine at the TU Dresden, Dresden, Germany
Background/Purpose: To analyze Stat1 and phosphorylated Stat1, the interleukin-6 (IL-6) receptor-Stat3 axis, and membrane bound tumor necrosis factor (mTNF) and TNF receptors 1 and 2…
Abstract Number: 3008 • 2015 ACR/ARHP Annual Meeting
Role of PTP4A1 Tyrosine Phosphatase in Systemic Sclerosis
Cristiano Sacchetti¹, Stephanie Stanford², Yunpeng Bai³, Zhong-Yin Zhang⁴, Amin Gholami⁵, Gregory Seumois⁶, Maria Piera-Velazquez⁷, Sergio A. Jimenez⁸ and Nunzio Bottini¹, ¹Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ²Cell Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, ³Indiana University, School of Medicine, Indianapolis, IN, ⁴Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, ⁵Bioinformatics Core, La Jolla Institute for Allergy and immunology, La Jolla, CA, ⁶Sequencing Facility, La Jolla Institute for Allergy and immunology, La Jolla, CA, ⁷Dermatology and Cutaneous Biology, Jefferson Medical College, Philadelphia, PA, ⁸Div Connective Tissue Diseases, Thomas Jefferson Univ, Philadelphia, PA
Background/Purpose: Systemic sclerosis (SSc) is a multi-system autoimmune connective tissue disorder that leads to fibrosis of the skin and internal organs, resulting in significant patient…
Abstract Number: 2302 • 2012 ACR/ARHP Annual Meeting
Secreted Frizzled-Related Protein 4 Induces a Profibrotic Phenotype in Systemic Sclerosis Fibroblasts by Activating a Non-Canonical WNT Signaling Pathway
Justin Gillespie¹, Paul Emery² and Francesco Del Galdo³, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Systemic Sclerosis (SSc) is a chronic fibrotic disease involving autoimmune activation, fibroproliferative vasculopathy and tissue fibrosis of skin and multiple internal organs. Several studies…
Abstract Number: 1492 • 2012 ACR/ARHP Annual Meeting
IL-13 Receptors and Signaling in the Dermal Fibroblasts From Patients with Systemic Sclerosis
Yuko Ota¹, Yasushi Kawaguchi¹, Atsushi Kitani², Kae Takagi¹, Hisae Ichida¹, Yasuhiro Katsumata¹, Takahisa Gono¹, Masanori Hanaoka¹, Yuko Okamoto¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Mucosal Immunity Section, NIAID/NIH, Bethesda, MD
Background/Purpose: Interleukin (IL)-13 is a pleiotropic cytokine involved in T helper type 2 cell immune response and in the development of fibrotic conditions such as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].